Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|October 25, 2023

EMA Creates Mechanism for Support during Drug Shortages

Author(s)Susan Haigney

The agency’s solidarity mechanism allows Member States to support each other when there is a shortage of a critical medicines.

The European Medicines Agency (EMA) announced on Oct. 24, 2023 that its Medicines Shortages Steering Group (MSSG) has developed a voluntary solidarity mechanism that allows European Union Members States to support each other during drug shortages. The mechanism was based on a plan set up during the COVID-19 pandemic and can only be used under limited conditions. It is a last resort to be used after Member States have exhausted other possibilities.

EU Member States may request assistance in obtaining medicine stocks from other member states if they face a critical shortage that has been escalated to the MSSG for coordination at European level. The mechanism is part of other shortages actions the MSSG can carry out and is part of the MSSG Toolkit, which includes recommendations for monitoring drug supplies. The mechanism and toolkit are part of actions the European Commission is taking to protect the EU from drug shortages.

Source: EMA


Related to this article

Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.